Amicus Therapeutics (FOLD)
Q2 2012 Earnings Call
August 7, 2012, 5:00 pm ET
John Crowley – Chairman, CEOBradley Campbell – Chief Business Officer Chip Baird – CFO David Lockhart – Chief Scientific Officer Analysts
Ritu Baral – Canaccord Anupam Rama – JP Morgan Joseph Schwartz – Leerink Swann Kim Lee - ThinkEquity Presentation Operator
Previous Statements by FOLD
» Amicus Therapeutics' CEO Hosts GSK Expanded Fabry Collaboration Call (Transcript)
» Amicus Therapeutics CEO Discusses Q3 2010 Results - Earnings Call Transcript
» Amicus Therapeutics Agreement with GSK - Call Transcript
» Amicus Therapeutics, Inc. Q2 2010 Earnings Call Transcript
Good afternoon and thank you for joining our conference call to discuss our second quarter 2012 financial results. Speaking on today's call we have John Crowley, our Chairman and Chief Executive Officer, Bradley Campbell, our Chief Business Officer, David Lockhart, our Chief Scientific Officer, and Chip Baird, our Chief Financial Officer. They are all available to participate in the Q&A session, as well. Pol Boudes, our Chief Medical Officer, is on vacation this week. Today's prepared remarks coincide with the slide presentation that is now available on our corporate website at www.amicusrx.com. The slides are located in the Investors section under Events and Presentations right below the webcast link. On Slide 2, we have a reference to forward-looking statements in this conference within the meaning of the Private Securities Reform Act of 1995 relating to the business, operations and financial conditions of Amicus including but not limited to preclinical and clinical development of Amicus' candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus' candidate drug products, the projected cash position for the company.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV